| Literature DB >> 36009151 |
Shengyu Guo1, Taotao Lin1, Rongcan Wu1, Zhenyu Wang1, Gang Chen1, Wenge Liu1.
Abstract
Objective. To explore the most important predictors of post-operative efficacy in patients with degenerative cervical myelopathy (DCM). Methods. From January 2013 to January 2019, 284 patients with DCM were enrolled. They were categorized based on the different surgical methods used: single anterior cervical decompression and fusion (ACDF) (n = 80), double ACDF (n = 56), three ACDF (n = 13), anterior cervical corpectomy and fusion (ACCF) (n = 63), anterior cervical hybrid decompression and fusion (ACHDF) (n = 25), laminoplasty (n = 38) and laminectomy and fusion (n = 9). The follow-up time was 2 years. The patients were divided into two groups based on the mJOA recovery rate at the last follow-up: Group A (the excellent improvement group, mJOA recovery rate >50%, n = 213) and Group B (the poor improvement group, mJOA recovery rate ≤50%, n = 71). The evaluated data included age, gender, BMI, duration of symptoms (months), smoking, drinking, number of lesion segments, surgical methods, surgical time, blood loss, the Charlson Comorbidity Index (CCI), CCI classification, imaging parameters (CL, T1S, C2-7SVA, CL (F), T1S (F), C2-7SVA (F), CL (E), T1S (E), C2-7SVA (E), CL (ROM), T1S (ROM) and C2-7SVA (ROM)), maximum spinal cord compression (MSCC), maximum canal compromise (MCC), Transverse area (TA), Transverse area ratio (TAR), compression ratio (CR) and the Coefficient compression ratio (CCR). The visual analog score (VAS), neck disability index (NDI), modified Japanese Orthopedic Association (mJOA) and mJOA recovery rate were used to assess cervical spinal function and quality of life. Results. We found that there was no significant difference in the baseline data among the different surgical groups and that there were only significant differences in the number of lesion segments, C2-7SVA, T1S (F), T1S (ROM), TA, CR, surgical time and blood loss. Therefore, there was comparability of the post-operative recovery among the different surgical groups, and we found that there were significant differences in age, the duration of symptoms, CL and pre-mJOA between Group A and Group B. A binary logistic regression analysis showed that the duration of the symptoms was an independent risk factor for post-operative efficacy in patients with DCM. Meanwhile, when the duration of symptoms was ≥6.5 months, the prognosis of patients was more likely to be poor, and the probability of a poor prognosis increased by 0.196 times for each additional month of symptom duration (p < 0.001, OR = 1.196). Conclusion. For patients with DCM (regardless of the number of lesion segments and the proposed surgical methods), the duration of symptoms was an independent risk factor for the post-operative efficacy. When the duration of symptoms was ≥6.5 months, the prognosis of patients was more likely to be poor, and the probability of a poor prognosis increased by 0.196 times for each additional month of symptom duration (p < 0.001, OR = 1.196).Entities:
Keywords: degenerative cervical myelopathy; mJOA; mJOA recovery rate; post-operative efficacy; pre-operative duration of symptoms
Year: 2022 PMID: 36009151 PMCID: PMC9405785 DOI: 10.3390/brainsci12081088
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1The summary of the details of patients excluded by inclusion criteria.
Figure 2Surgical methods. (A) Single ACDF. (B) Double ACDF. (C) Three ACDF. (D) ACCF. (E) ACHDF. (F) Laminoplasty. (G) Laminectomy and fusion.
Figure 3Charlson Comorbidity Index (CCI).
The measuring methods of cervical sagittal parameters in the radiographs and MSCC, MCC, TA, TAR, CR, CCR in MRI.
| Cervical Sagittal Parameters | The Measuring Method ( |
|---|---|
| C2-C7 cobb angle (CL) | The cobb angle between the C2 lower endplate and C7 lower endplate, with (+) for lordosis and (−) for kyphosis. |
| T1 slope (T1S) | The angle between a horizontal line and the T1 superior endplate. |
| C2-7 sagittal vertical axis (SVA) | The distance between the plumb line through the center of C2 and the plumb line of the posterior of the C7 upper endplate. |
| Parameters in MRI | The measuring method ( |
| Maximum spinal cord compression (MSCC) | A midsagittal T2-WI of a patient with DCM, including the width of the spinal cord at the most compressed site (di) and the width of the spinal cord at normal sites above (da) and below (db) the site of maximum compression. |
| Maximum canal compromise (MCC) | A midsagittal T2-WI of a patient with DCM, including the width of the canal at the most stenotic site (Di) and the width of the spinal canal at normal sites above (Da) and below (Db) the canal stenosis. |
| Transverse area (TA) | A midsagittal T2-WI of a patient with DCM, the cross-sectional area of the spinal cord at the most severely compressed segment was measured. |
| Transverse area ratio (TAR) | A midsagittal T2-WI of a patient with DCM, including the cross-sectional area of compressed spinal cord (TA) and the cross-sectional area of upper and lower normal spinal cord (TA1,TA2). |
| Compression ratio (CR) | A midsagittal T2-WI of a patient with DCM, a ratio between the anteroposterior diameter and the transverse diameter on the cross-sectional of spinal cord compression. |
| Coefficient compression ratio (CCR) | A midsagittal T2-WI of a patient with DCM, including the CR of compressed spinal cord (CR1) and the CR of upper and lower normal spinal cord (CR2,CR3). |
Figure 4Sagittal radiograph of cervical spine with representative measurements. (A) C2-C7 cobb angle (CL), T1 slope (T1S). (B) C2-7SVA.
Figure 5MRI parameter measurement of cervical spine. (A) MSCC. (B) MCC. (C) TA. (D) CR.
Basic data and comparison among different surgical methods group.
| Single-ACDF ( | Double-ACDF ( | Three-ACDF ( | ACCF ( | ACHDF ( | Laminoplasty ( | Laminectomy and Fusion ( | × 2/F | ||
|---|---|---|---|---|---|---|---|---|---|
| Age | 53.1 ± 10.0 | 56.6 ± 11.9 | 50.1 ± 9.2 | 54.3 ± 11.5 | 57.6 ± 9.9 | 58.2 ± 10.3 | 56.6 ± 6.8 | 1.985 | 0.068 |
| Gender (Female, | 36 (45%) | 24 (42.9%) | 4 (30.8%) | 23 (36.5%) | 4 (16%) | 9 (23.7%) | 3 (33.3%) | 10.942 | 0.09 |
| BMI | 24.1 ± 2.7 | 23.4 ± 3.2 | 24.1 ± 2.2 | 23.6 ± 3.1 | 23.2 ± 2.9 | 23.5 ± 3.0 | 24.3 ± 2.7 | 0.583 | 0.744 |
| Duration of symptoms (months) | 3.5 (2.0~8.0) | 3.5 (1.0~12.0) | 2.0 (1.0~6.0) | 4.0 (1.0~12.0) | 4.0 (1.5~12.0) | 3.0 (1.0~12.0) | 2.0 (1.5~7.5) | 1.856 | 0.932 |
| Smoking ( | 18 (22.5%) | 19 (33.9%) | 3 (23.1%) | 21 (33.3%) | 10 (40%) | 14 (36.8%) | 2 (22.2%) | 5.363 | 0.498 |
| Drinking ( | 23 (28.8%) | 14 (25%) | 3 (23.1%) | 19 (30.2%) | 9 (36%) | 9 (23.7%) | 3 (33.3%) | 1.835 | 0.934 |
| CCI | 2.0 (0.0~3.0) | 2.0 (1.0~3.0) | 1.0 (0.0~2.5) | 2.0 (0.0~3.0) | 2.0 (0.5~3.5) | 2.0 (0.0~3.0) | 3.0 (1.5~3.5) | 9.735 | 0.136 |
| CCI classification (0–1 point, | 36 (45%) | 21 (37.5%) | 8 (61.5%) | 31 (49.2%) | 8 (32%) | 16 (42.1%) | 2 (22.2%) | 6.468 | 0.373 |
| CL | 16.9 ± 9.7 | 14.8 ± 10.1 | 14.4 ± 7.8 | 17.1 ± 9.5 | 17.5 ± 10.8 | 15.6 ± 9.9 | 12.8 ± 5.1 | 0.727 | 0.629 |
| T1S | 24.8 ± 8.2 | 24.6 ± 7.7 | 21.2 ± 4.8 | 26.8 ± 6.6 | 25.2 ± 7.5 | 25.5 ± 7.2 | 26.0 ± 5.7 | 1.222 | 0.295 |
| C2-7SVA (mm) | 16.0 ± 11.0 | 17.0 ± 12.1 | 14.7 ± 9.5 | 14.4 ± 10.9 | 15.0 ± 11.4 | 14.6 ± 10.7 | 28.4 ± 13.1 | 2.260 | 0.038 * |
| CL(F) | −18.9 ± 9.8 | −17.4 ± 10.1 | −17.8 ± 8.7 | −15.9 ± 9.6 | −18.4 ± 8.8 | −19.3 ± 8.7 | −15.7 ± 9.5 | 0.873 | 0.515 |
| T1S(F) | 32.2 ± 10.3 | 34.2 ± 10.0 | 28.2 ± 6.4 | 37.7 ± 7.7 | 36.3 ± 5.7 | 33.3 ± 7.2 | 31.1 ± 6.1 | 3.978 | 0.001 ** |
| C2-7SVA (F) | 62.3 ± 16.8 | 63.3 ± 13.4 | 53.6 ± 14.7 | 64.5 ± 11.6 | 65.8 ± 9.6 | 62.1 ± 11.0 | 63.0 ± 12.7 | 1.435 | 0.201 |
| CL(E) | 28.9 ± 11.9 | 27.1 ± 13.0 | 21.8 ± 8.8 | 28.1 ± 11.6 | 24.6 ± 12.0 | 25.9 ± 12.3 | 25.1 ± 10.2 | 1.083 | 0.373 |
| T1S(E) | 22.1 ± 9.8 | 22.3 ± 7.8 | 17.5 ± 6.2 | 23.0 ± 9.7 | 20.5 ± 8.8 | 22.4 ± 7.9 | 23.2 ± 5.2 | 0.867 | 0.519 |
| C2-7SVA (E) | 1.5 (−12.7~7.5) | 3.7 (−5.9~8.9) | 5.8 (−5.3~16.0) | 2.0 (−15.8~6.4) | 3.0 (−15.2~11.3) | −1.8 (−9.7~7.0) | 7.5 (3.7~14.0) | 11.447 | 0.075 |
| CL(ROM) | 47.8 ± 14.3 | 44.5 ± 13.2 | 39.5 ± 11.2 | 44.0 ± 13.6 | 43.0 ± 14.5 | 45.3 ± 13.1 | 40.8 ± 11.8 | 1.202 | 0.305 |
| T1S(ROM) | −10.1 ± 9.0 | −11.8 ± 10.2 | −10.8 ± 7.1 | −14.7 ± 12.1 | −15.8 ± 9.5 | −11.0 ± 8.2 | −7.9 ± 6.2 | 2.323 | 0.033 * |
| C2-7SVA (ROM) | −63.1 ± 24.7 | −60.8 ± 20.1 | −49.1 ± 19.2 | −68.1 ± 21.2 | −67.2 ± 21.0 | −63.2 ± 18.0 | −54.8 ± 17.1 | 1.976 | 0.069 |
| MSCC | 0.39 ± 0.14 | 0.40 ± 0.11 | 0.44 ± 0.15 | 0.44 ± 0.12 | 0.45 ± 0.14 | 0.42 ± 0.11 | 0.46 ± 0.10 | 1.709 | 0.119 |
| MCC | 0.50 ± 0.15 | 0.52 ± 0.13 | 0.56 ± 0.11 | 0.56 ± 0.12 | 0.55 ± 0.15 | 0.52 ± 0.13 | 0.55 ± 0.14 | 1.420 | 0.207 |
| TA | 0.52 ± 0.15 | 0.48 ± 0.11 | 0.50 ± 0.08 | 0.44 ± 0.13 | 0.44 ± 0.15 | 0.45 ± 0.14 | 0.49 ± 0.22 | 2.748 | 0.013 * |
| TAR | 0.40 ± 0.13 | 0.43 ± 0.12 | 0.43 ± 0.09 | 0.46 ± 0.12 | 0.45 ± 0.14 | 0.45 ± 0.11 | 0.48 ± 0.11 | 1.793 | 0.1 |
| CR | 0.26 ± 0.08 | 0.24 ± 0.07 | 0.22 ± 0.07 | 0.21 ± 0.08 | 0.21 ± 0.07 | 0.23 ± 0.09 | 0.22 ± 0.06 | 2.784 | 0.012 * |
| CCR | 0.44 ± 0.15 | 0.46 ± 0.13 | 0.50 ± 0.14 | 0.51 ± 0.14 | 0.50 ± 0.16 | 0.49 ± 0.13 | 0.46 ± 0.13 | 1.843 | 0.091 |
| Pre-VAS | 4.1 ± 2.1 | 4.4 ± 2.3 | 4.1 ± 2.7 | 4.4 ± 2.4 | 5.0 ± 2.5 | 4.1 ± 2.5 | 4.7 ± 2.1 | 0.607 | 0.725 |
| Pre-NDI | 15.8 ± 8.3 | 17.1 ± 9.3 | 17.0 ± 10.8 | 17.8 ± 9.2 | 17.8 ± 9.1 | 13.9 ± 9.4 | 19.7 ± 7.8 | 1.127 | 0.347 |
| Pre-mJOA | 9.8 ± 1.5 | 9.6 ± 1.4 | 9.3 ± 0.9 | 9.3 ± 1.3 | 9.0 ± 1.3 | 9.3 ± 1.2 | 9.0 ± 1.6 | 1.680 | 0.126 |
| Surgical time (min) | 100.2 ± 14.9 | 133.5 ± 16.5 | 158.7 ± 13.7 | 118.1 ± 16.6 | 140.5 ± 18.4 | 139.4 ± 13.8 | 179.2 ± 19.5 | 73.238 | <0.001 ** |
| Blood loss (mL) | 51.1 ± 16.9 | 74.7 ± 20.8 | 102.3 ± 10.7 | 192.7 ± 34.0 | 220.2 ± 36.8 | 174.5 ± 31.6 | 289.4 ± 46.9 | 320.761 | <0.001 ** |
| Post-VAS (1) | 2.1 ± 0.9 | 2.1 ± 1.1 | 2.7 ± 0.9 | 2.1 ± 1.1 | 2.1 ± 1.2 | 2.1 ± 1.1 | 2.8 ± 0.8 | 1.181 | 0.316 |
| Post-NDI (1) | 8.0 ± 4.6 | 9.4 ± 5.1 | 9.9 ± 4.7 | 8.8 ± 5.2 | 9.5 ± 5.4 | 8.0 ± 5.4 | 9.3 ± 4.4 | 0.829 | 0.548 |
| Post-mJOA (1) | 15.6 ± 1.5 | 15.2 ± 1.8 | 16.2 ± 1.2 | 15.5 ± 1.9 | 14.9 ± 2.0 | 15.0 ± 2.4 | 15.1 ± 1.9 | 1.393 | 0.217 |
| mJOA recovery rate% (1) | 69.6 ± 19.9 | 65.4 ± 22.7 | 77.4 ± 17.7 | 71.6 ± 21.1 | 65.6 ± 20.5 | 64.9 ± 27.3 | 68.3 ± 20.0 | 1.041 | 0.399 |
| Post-VAS (3) | 1.8 ± 0.9 | 1.7 ± 0.9 | 1.5 ± 1.0 | 1.8 ± 0.9 | 1.9 ± 1.0 | 1.9 ± 0.9 | 1.9 ± 0.6 | 0.456 | 0.840 |
| Post-NDI (3) | 5.9 ± 4.3 | 7.1 ± 4.8 | 7.8 ± 3.8 | 7.0 ± 4.4 | 7.8 ± 4.4 | 5.9 ± 4.2 | 7.9 ± 4.1 | 1.280 | 0.266 |
| Post-mJOA (3) | 15.5 ± 1.5 | 15.2 ± 1.8 | 16.1 ± 1.0 | 15.6 ± 1.7 | 14.9 ± 2.0 | 15.0 ± 2.3 | 15.1 ± 1.9 | 1.293 | 0.260 |
| mJOA recovery rate% (3) | 68.9 ± 19.8 | 65.6 ± 22.4 | 76.6 ± 16.1 | 71.8 ± 20.0 | 65.7 ± 20.8 | 64.9 ± 26.4 | 68.3 ± 20.0 | 0.981 | 0.438 |
| Post-VAS (6) | 1.6 ± 0.9 | 1.6 ± 0.8 | 1.3 ± 0.6 | 1.7 ± 0.8 | 1.7 ± 0.7 | 1.7 ± 0.8 | 1.7 ± 0.5 | 0.648 | 0.692 |
| Post-NDI (6) | 5.7 ± 4.7 | 6.2 ± 4.3 | 6.5 ± 2.4 | 6.4 ± 4.2 | 6.8 ± 3.2 | 5.8 ± 4.3 | 7.8 ± 3.1 | 0.634 | 0.703 |
| Post-mJOA (6) | 15.5 ± 1.5 | 15.1 ± 1.8 | 15.9 ± 1.0 | 15.5 ± 1.8 | 14.9 ± 2.0 | 15.0 ± 2.3 | 15.0 ± 2.1 | 1.064 | 0.384 |
| mJOA recovery rate% (6) | 67.9 ± 20.0 | 64.6 ± 22.2 | 74.9 ± 15.2 | 70.9 ± 20.1 | 65.7 ± 20.8 | 64.6 ± 26.9 | 67.2 ± 21.4 | 0.830 | 0.548 |
| Post-VAS (12) | 1.7 ± 1.0 | 1.5 ± 0.7 | 1.3 ± 0.6 | 1.7 ± 0.8 | 1.8 ± 0.8 | 1.7 ± 0.8 | 1.7 ± 0.5 | 0.776 | 0.589 |
| Post-NDI (12) | 5.5 ± 4.3 | 5.6 ± 3.7 | 6.4 ± 1.7 | 6.3 ± 4.0 | 6.1 ± 4.6 | 5.6 ± 4.1 | 7.6 ± 2.8 | 0.582 | 0.745 |
| Post-mJOA (12) | 15.4 ± 1.5 | 15.0 ± 1.9 | 15.8 ± 1.0 | 15.4 ± 1.8 | 14.8 ± 1.9 | 14.7 ± 2.3 | 15.0 ± 2.1 | 1.124 | 0.348 |
| mJOA recovery rate% (12) | 66.8 ± 20.2 | 63.1 ± 23.4 | 73.2 ± 15.4 | 69.4 ± 20.6 | 64.8 ± 20.0 | 62.3 ± 26.7 | 67.2 ± 21.4 | 0.876 | 0.513 |
| Post-VAS (24) | 1.8 ± 1.0 | 1.6 ± 0.8 | 1.3 ± 0.6 | 1.8 ± 0.8 | 2.1 ± 1.1 | 1.8 ± 0.8 | 1.8 ± 0.7 | 1.692 | 0.123 |
| Post-NDI (24) | 6.0 ± 4.8 | 7.7 ± 5.1 | 6.3 ± 1.1 | 6.5 ± 4.3 | 7.8 ± 6.0 | 5.9 ± 4.1 | 8.0 ± 2.0 | 1.306 | 0.255 |
| Post-mJOA (24) | 15.1 ± 1.6 | 14.6 ± 1.9 | 15.4 ± 1.0 | 15.1 ± 1.9 | 14.3 ± 2.2 | 14.5 ± 2.3 | 14.2 ± 1.9 | 1.475 | 0.187 |
| mJOA recovery rate% (24) | 63.0 ± 20.8 | 59.0 ± 24.6 | 68.4 ± 17.9 | 66.8 ± 21.0 | 58.9 ± 23.0 | 59.1 ± 26.1 | 58.1 ± 19.3 | 1.081 | 0.374 |
* and lighter gray shading signifies that p < 0.05. ** and dark gray shading signifies that p < 0.01.
Basic data and comparison between Group A and Group B.
| Group A | Group B | T/× 2/Z | ||
|---|---|---|---|---|
| Age | 54.3 ± 10.8 | 57.6 ± 10.4 | 2.244 | 0.026 * |
| Gender (Female, | 75 (35.2%) | 28 (39.4%) | 0.411 | 0.521 |
| BMI | 23.8 ± 3.0 | 23.5 ± 2.5 | −0.759 | 0.448 |
| Duration of symptoms (months) | 2.0 (1.0~5.0) | 24.0 (12.0~36.0) | −11.357 | <0.001 ** |
| Smoking ( | 68 (31.9%) | 19 (26.8%) | 0.668 | 0.414 |
| Drinking ( | 64 (30.0%) | 16 (22.5%) | 1.485 | 0.223 |
| Number of lesion segments—single | 60 (28.2%) | 20 (28.2%) | 0.000 | 1.000 |
| ≥2 | 153 (71.8%) | 51 (71.8%) | ||
| Surgical methods—Single ACDF | 60 (28.2%) | 20 (28.2%) | 6.715 | 0.348 |
| —Double ACDF | 41 (19.3%) | 15 (21.1%) | ||
| —Three ACDF | 12 (5.6%) | 1 (1.4%) | ||
| —ACCF | 51 (23.9%) | 12 (16.9%) | ||
| —ACHDF | 15 (7.0%) | 10 (14.1%) | ||
| —Laminoplasty | 27 (12.7%) | 11 (15.5%) | ||
| —Laminectomy and fusion | 7 (3.3%) | 2 (2.8%) | ||
| Surgical time (min) | 124.8 ± 25.6 | 124.4 ± 24.7 | −0.112 | 0.911 |
| Blood loss (mL) | 128.4 ± 76.0 | 128.5 ± 77.0 | 0.006 | 0.995 |
| CCI | 1.75 ± 1.6 | 2.1 ± 1.4 | 1.533 | 0.127 |
| CCI classification—0–1 point | 96 (45.1%) | 26 (36.6%) | 1.552 | 0.213 |
| ≥2 points | 117 (54.9%) | 45 (63.4%) | ||
| CL | 16.8 ± 9.9 | 14.1 ± 8.9 | 2.059 | 0.040 * |
| T1S | 25.5 ± 7.6 | 24.4 ± 6.8 | −1.027 | 0.305 |
| C2-7SVA (mm) | 15.9 ± 11.7 | 15.9 ± 10.3 | 0.007 | 0.994 |
| CL (F) | −17.9 ± 9.8 | −17.4 ± 8.6 | 0.401 | 0.689 |
| T1S (F) | 34.1 ± 9.2 | 34.1 ± 8.2 | −0.043 | 0.965 |
| C2-7SVA (F) | 62.8 ± 13.6 | 63.3 ± 13.7 | 0.300 | 0.764 |
| CL (E) | 26.9 ± 12.1 | 27.9 ± 11.5 | 0.655 | 0.513 |
| T1S (E) | 22.1 ± 9.0 | 21.8 ± 8.2 | −0.313 | 0.755 |
| C2-7SVA (E) | 2.2 (−11.1~7.8) | 3.6 (−9.5~8.8) | −0.222 | 0.824 |
| CL (ROM) | 44.8 ± 14.0 | 45.4 ± 12.7 | 0.294 | 0.769 |
| T1S (ROM) | −12.0 ± 10.3 | −12.3 ± 9.0 | −0.238 | 0.812 |
| C2-7SVA (ROM) | −62.9 ± 22.0 | −64.3 ± 20.8 | −0.469 | 0.640 |
| MSCC | 0.42 ± 0.12 | 0.41 ± 0.14 | −0.731 | 0.466 |
| MCC | 0.53 ± 0.13 | 0.52 ± 0.17 | −0.319 | 0.750 |
| TA | 0.48 ± 0.13 | 0.48 ± 0.16 | −0.109 | 0.913 |
| TAR | 0.44 ± 0.11 | 0.41 ± 0.15 | −1.382 | 0.170 |
| CR | 0.23 ± 0.08 | 0.23 ± 0.09 | −0.457 | 0.648 |
| CCR | 0.48 ± 0.13 | 0.46 ± 0.17 | −0.868 | 0.387 |
| Pre-VAS | 4.3 ± 2.4 | 4.4 ± 2.2 | 0.117 | 0.907 |
| Pre-NDI | 16.6 ± 9.3 | 16.6 ± 8.3 | 0.008 | 0.994 |
| Pre-mJOA | 9.3 ± 1.3 | 9.8 ± 1.5 | 2.087 | 0.039 * |
* and lighter gray shading signifies that p < 0.05. ** and dark gray shading signifies that p < 0.01.
Figure 6(A) Age difference between the two groups (independent-sample t-test). (B) CL difference between the two groups (independent-sample t-test). (C) Pre-mJOA difference between the two groups (independent-sample t-test). (D) Duration of symptoms (months) difference between the two groups (Mann–Whitney U test). Asterisks represent data with large bias.
Using Binary Logistic Regression Analysis to Judge Independent Risk Factors.
| B | OR | 95% Confidence Interval of OR | |||
|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||
| Age | 0.007 | 0.716 | 1.007 | 0.972 | 1.043 |
| Duration of symptoms (M) | 0.179 | <0.001 ** | 1.196 | 1.135 | 1.261 |
| CL | −0.025 | 0.194 | 0.975 | 0.939 | 1.013 |
| Pre-mJOA | 0.118 | 0.381 | 1.126 | 0.864 | 1.467 |
** and dark gray shading signifies that p < 0.05.
Figure 7ROC curve (age, duration of symptoms, CL and pre-mJOA).
Correlation between basic data and functional scores.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Age | −0.147 * | −0.172 ** | 0.049 | −0.116 | −0.074 | −0.129 * | −0.129 * | −0.056 | −0.069 | −0.127 * | −0.125 * | −0.072 | −0.080 | −0.129 * | −0.129 * | −0.105 | −0.096 | −0.122 * | −0.122 * | −0.102 | −0.056 | −0.144 * | −0.149 * |
| Gender | −0.076 | −0.089 | −0.074 | −0.130 * | −0.119 * | 0.044 | 0.064 | −0.055 | −0.081 | 0.032 | 0.052 | −0.069 | −0.034 | 0.039 | 0.060 | −0.050 | 0.004 | 0.049 | 0.072 | −0.023 | −0.002 | 0.018 | 0.040 |
| BMI | −0.004 | −0.013 | 0.004 | 0.033 | −0.015 | −0.024 | −0.032 | −0.030 | −0.027 | −0.032 | −0.038 | −0.036 | −0.038 | −0.047 | −0.055 | −0.075 | −0.063 | −0.040 | −0.049 | −0.125 * | −0.109 | −0.019 | −0.032 |
| Duration of symptoms | −0.061 | −0.061 | 0.201 ** | 0.198 ** | 0.206 ** | −0.567 ** | −0.638 ** | 0.297 ** | 0.267 ** | −0.557 ** | −0.629 ** | 0.283 ** | 0.266 ** | −0.559 ** | −0.636 ** | 0.271 ** | 0.249 ** | −0.560 ** | −0.638 ** | 0.227 ** | 0.252 ** | −0.552 ** | −0.640 ** |
| Smoking | −0.008 | −0.028 | −0.027 | −0.042 | −0.012 | 0.096 | 0.101 | −0.039 | −0.036 | 0.082 | 0.089 | −0.057 | −0.019 | 0.074 | 0.081 | −0.034 | 0.004 | 0.083 | 0.093 | −0.020 | −0.006 | 0.076 | 0.081 |
| Drinking | −0.064 | −0.076 | −0.010 | −0.079 | −0.060 | 0.053 | 0.055 | −0.070 | −0.087 | 0.047 | 0.050 | −0.102 | −0.090 | 0.045 | 0.050 | −0.070 | −0.053 | 0.047 | 0.054 | −0.045 | −0.061 | 0.023 | 0.027 |
| lesion number | 0.057 | 0.055 | −0.144 * | 0.042 | 0.091 | −0.079 | −0.029 | 0.018 | 0.110 | −0.064 | −0.014 | 0.016 | 0.075 | −0.062 | −0.009 | −0.028 | 0.053 | −0.072 | −0.018 | −0.063 | 0.089 | −0.073 | −0.020 |
| CCI | −0.135 * | −0.119 * | 0.011 | −0.016 | 0.012 | −0.032 | −0.067 | −0.006 | 0.055 | −0.020 | −0.054 | −0.005 | 0.042 | −0.021 | −0.054 | −0.021 | 0.019 | −0.004 | −0.038 | 0.023 | 0.088 | −0.048 | −0.082 |
| CCI classification | −0.067 | −0.062 | 0.029 | −0.005 | 0.031 | −0.035 | −0.074 | 0.025 | 0.049 | −0.019 | −0.058 | 0.020 | 0.052 | −0.025 | −0.063 | 0.022 | 0.022 | −0.011 | −0.050 | 0.061 | 0.079 | −0.037 | −0.074 |
| Pre-VAS | 1 | 0.947 ** | −0.010 | 0.604 ** | 0.605 ** | −0.030 | −0.024 | 0.476 ** | 0.46 9 ** | −0.019 | −0.013 | 0.402 ** | 0.406 ** | −0.006 | 0.002 | 0.381 ** | 0.382 ** | −0.015 | −0.008 | 0.394 ** | 0.340 ** | 0.000 | 0.010 |
| Pre-NDI | 1 | −0.026 | 0.597 ** | 0.627 ** | −0.025 | −0.020 | 0.464 ** | 0.498 ** | −0.011 | −0.007 | 0.396 ** | 0.433 ** | 0.000 | 0.007 | 0.370 ** | 0.406 ** | −0.002 | 0.002 | 0.385 ** | 0.368 ** | 0.012 | 0.018 | |
| Pre-mJOA | 1 | 0.022 | −0.021 | 0.048 | −0.199 ** | 0.045 | 0.031 | 0.051 | −0.204 ** | 0.061 | 0.010 | 0.065 | −0.196 ** | 0.056 | −0.020 | 0.065 | −0.197 ** | 0.026 | 0.015 | 0.097 | −0.189 ** | ||
| Correlation between Pre-operative Imaging Parameters and Functional Scores. | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CL | −0.184 ** | −0.186 ** | 0.020 | −0.094 | −0.121 * | 0.131 * | 0.129 * | −0.079 | −0.074 | 0.125 * | 0.124 * | −0.056 | −0.072 | 0.113 | 0.113 | −0.048 | −0.050 | 0.126 * | 0.127 * | −0.018 | −0.056 | 0.135 * | 0.135 * |
| T1S | −0.100 | −0.091 | 0.100 | −0.120 * | −0.134 * | 0.125 * | 0.105 | −0.062 | −0.041 | 0.130 * | 0.108 | −0.017 | −0.021 | 0.125 * | 0.105 | −0.019 | −0.001 | 0.135 * | 0.115 | 0.003 | 0.002 | 0.147 * | 0.122 * |
| C2-7SVA | 0.033 | 0.039 | 0.021 | −0.031 | −0.070 | 0.040 | 0.033 | −0.021 | −0.026 | 0.044 | 0.036 | −0.003 | 0.022 | 0.049 | 0.040 | −0.008 | 0.046 | 0.051 | 0.040 | 0.016 | 0.055 | 0.013 | 0.003 |
| CL(F) | −0.155 ** | −0.113 | 0.026 | −0.118 * | −0.042 | 0.035 | 0.026 | −0.072 | −0.019 | 0.029 | 0.018 | −0.045 | −0.011 | 0.039 | 0.030 | −0.034 | 0.022 | 0.054 | 0.045 | −0.033 | 0.016 | 0.041 | 0.027 |
| T1S(F) | −0.034 | −0.012 | 0.022 | −0.107 | −0.057 | 0.045 | 0.065 | −0.021 | −0.006 | 0.063 | 0.081 | −0.011 | 0.017 | 0.058 | 0.077 | −0.012 | 0.023 | 0.060 | 0.080 | 0.014 | 0.030 | 0.081 | 0.096 |
| C2-7SVA (F) | 0.054 | 0.053 | −0.040 | 0.003 | −0.005 | −0.028 | −0.001 | 0.058 | 0.030 | −0.014 | 0.013 | 0.052 | 0.082 | −0.027 | 0.000 | 0.054 | 0.063 | −0.024 | 0.003 | 0.051 | 0.046 | −0.017 | 0.012 |
| CL (E) | −0.051 | −0.030 | 0.057 | 0.028 | 0.046 | −0.025 | −0.033 | 0.039 | 0.045 | −0.027 | −0.037 | 0.071 | 0.071 | −0.042 | −0.052 | 0.089 | 0.084 | −0.026 | −0.034 | 0.101 | 0.067 | −0.007 | −0.018 |
| T1S (E) | −0.056 | −0.042 | 0.058 | −0.055 | −0.064 | 0.089 | 0.065 | −0.050 | 0.010 | 0.092 | 0.068 | 0.012 | 0.026 | 0.088 | 0.065 | 0.039 | 0.072 | 0.092 | 0.068 | 0.062 | 0.093 | 0.109 | 0.082 |
| C2-7SVA (E) | 0.002 | 0.012 | −0.008 | −0.036 | −0.066 | 0.104 | 0.097 | −0.070 | −0.003 | 0.091 | 0.087 | −0.069 | −0.027 | 0.098 | 0.096 | −0.057 | 0.002 | 0.098 | 0.093 | −0.050 | 0.021 | 0.077 | 0.074 |
| CL (ROM) | 0.063 | 0.053 | 0.032 | 0.107 | 0.069 | −0.046 | −0.046 | 0.084 | 0.053 | −0.044 | −0.045 | 0.094 | 0.070 | −0.064 | −0.066 | 0.102 | 0.059 | −0.061 | −0.061 | 0.112 | 0.047 | −0.035 | −0.035 |
| T1S (ROM) | −0.019 | −0.026 | 0.032 | 0.048 | −0.005 | 0.039 | −0.001 | −0.025 | 0.014 | 0.025 | −0.013 | 0.021 | 0.007 | 0.025 | −0.012 | 0.046 | 0.043 | 0.027 | −0.012 | 0.042 | 0.056 | 0.024 | −0.014 |
| C2-7SVA (ROM) | −0.032 | −0.026 | 0.020 | −0.026 | −0.041 | 0.087 | 0.065 | −0.083 | −0.020 | 0.069 | 0.050 | −0.078 | −0.069 | 0.082 | 0.064 | −0.072 | −0.038 | 0.081 | 0.060 | −0.065 | −0.015 | 0.062 | 0.042 |
| MSCC | −0.008 | −0.027 | −0.621 ** | −0.007 | 0.028 | −0.031 | 0.121 * | −0.016 | −0.019 | −0.028 | 0.129 * | −0.070 | −0.021 | -0.040 | 0.122 * | −0.051 | −0.027 | −0.039 | 0.124 * | −0.037 | −0.032 | −0.061 | 0.117 * |
| MCC | −0.026 | −0.035 | −0.517 ** | 0.019 | 0.041 | −0.045 | 0.091 | 0.015 | 0.003 | −0.051 | 0.086 | −0.038 | −0.017 | −0.059 | 0.084 | −0.027 | −0.018 | −0.060 | 0.084 | −0.022 | −0.019 | −0.084 | 0.073 |
| TA | −0.009 | 0.001 | 0.714 ** | −0.037 | −0.068 | 0.150 * | −0.030 | −0.071 | −0.050 | 0.143 * | −0.042 | −0.042 | −0.064 | 0.147 * | −0.042 | −0.053 | −0.075 | 0.146 * | −0.044 | −0.073 | −0.050 | 0.176 ** | −0.031 |
| TAR | −0.028 | −0.034 | −0.852 ** | −0.012 | 0.022 | −0.082 | 0.137 * | −0.019 | −0.024 | −0.078 | 0.148 * | −0.049 | −0.015 | −0.088 | 0.143 * | −0.036 | 0.019 | −0.085 | 0.148 * | −0.006 | 0.003 | −0.123 * | 0.130 * |
| CR | 0.045 | 0.041 | 0.529 ** | −0.003 | −0.041 | 0.099 | −0.029 | −0.008 | −0.009 | 0.098 | −0.034 | −0.005 | −0.037 | 0.108 | −0.029 | 0.015 | −0.020 | 0.103 | −0.037 | 0.004 | −0.027 | 0.137 * | −0.015 |
| CCR | −0.013 | −0.038 | −0.618 ** | −0.039 | −0.013 | −0.037 | 0.125 * | −0.022 | −0.051 | −0.032 | 0.133 * | −0.062 | −0.044 | −0.047 | 0.125 * | −0.070 | −0.052 | −0.047 | 0.126 * | −0.068 | −0.058 | −0.072 | 0.117 * |
* and lighter gray shading signifies that the correlation is significant at the 0.05 level (2-tailed). ** and dark gray shading signifies that the correlation is significant at the 0.01 level (2-tailed).